Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005

@inproceedings{Benitz2009EpidemiologyOI,
  title={Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005},
  author={William E. Benitz},
  year={2009}
}
The changing epidemiology of group B streptococcus bloodstream infection: a multi-national population-based assessment
TLDR
While marked variability in the incidence of GBS BSI was observed among these regions, it was consistently found that rates increased among older adults, especially in association with diabetes.
Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo
TLDR
It is concluded that GBS Sia mimicry influences host innate immune and inflammatory responses in vivo through engagement of an inhibitory Siglec, with the ultimate outcome of the host response varying depending upon the site, stage and magnitude of infection.
Structural vaccinology to thwart antigenic variation in microbial pathogens
TLDR
Combining structural biology approaches with domain mapping of protective epitopes, Nuccitelli et al. (3) string together six antigenic variants of the same functional unit into a single recombinant antigen that elicits antibody-mediated vaccine protection against all of S. agalactiae isolates examined.
Streptococcus agalactiae Toxic Shock-Like Syndrome
TLDR
The importance of early supportive management, antimicrobial therapy, and surgical intervention in patients with invasive Streptococcus agalactiae infection who present with shock is stressed.
Erratum to: Equality in Obstetrical Care: Racial/Ethnic Variation in Group B Streptococcus Screening
The online version of the original article can be found under doi:10.1007/s10995-010-0682-8.
Group B Streptococcus Colonization, Antibiotic Susceptibility, and Serotype Distribution among Saudi Pregnant Women
TLDR
GBS colonization was evident among pregnant women, and resistance to erythromycin and clindamycin was predominant among serotypes Ia, III, and V, the first to report the distribution of GBS serotypes based on molecular genotyping in Saudi Arabia.
Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?
TLDR
In adults with CF, GBS is uncommon and is generally a transient colonizer of the lower airways, despite the presence of structural lung disease and impaired innate immunity in CF, incident GBS infection did not increase PEx risk, PEx frequency, rate of lung function decline, or other adverse clinical outcomes.
Immune Response to Invasive Group B Streptococcus Disease in Adults
TLDR
Antibodies to capsular polysaccharides and pilus proteins develop in recovering adults as well as in patients with central nervous system injuries.
...
...

References

SHOWING 1-3 OF 3 REFERENCES
Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005.
TLDR
Among infants from birth through 6 days, the incidence of group B streptococcal disease was lower in 2003-2005 relative to 1999-2001, and this reduction coincided with the release of revised disease prevention guidelines in 2002.
Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.
TLDR
Over a six-year period, there has been a substantial decline in the incidence of group B streptococcal disease in newborns, including a major reduction in the excess incidence of these infections in black infants.
A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates.
TLDR
Routine screening for group B streptococcus during pregnancy prevents more cases of early-onset disease than the risk-based approach, and recommendations that endorse both strategies as equivalent warrant reconsideration.